STOP Persistent AF PAS
NCT05005949
Recruiting
The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Hartford Hospital, Hartford, Connecticut +16 locations
Conditions: Persistent Atrial Fibrillation
Register for Updates
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
NCT05135559
Recruiting
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin with a pen-injector. The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for pur... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/19/2025
Locations: Rady Childrens Hosp San Diego, San Diego, California +99 locations
Conditions: Haemophilia A and B With and Without Inhibitors
Register for Updates
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT05363111
Recruiting
This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In 111-DOTA-daratumumab (111In-DOTA-daratumumab) in treating patients with multiple myeloma that does not respond to treatment (refractory) or that has come back (recurrent). Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. 111In-DOTA-daratumumab and 225Ac-DOTA-daratumum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
NCT05369052
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: New Hope Research Development, Corona, California +15 locations
Conditions: Diabetic Foot Infection
Register for Updates
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
NCT05423210
Recruiting
This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition to two doses of Atezolizumab (Tecentriq), an FDA approved PD- L1 inhibitor drug, 840 mg IV, at the beginning and at the end of the two-week time period, concomitantly with FSRT. After this initial two weeks treatment the patients will undergo craniotomy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Stony Brook University Hospital, Stony Brook, New York
Conditions: Glioblastoma Multiforme
Register for Updates
RESPONDER-HF Trial
NCT05425459
Recruiting
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/19/2025
Locations: Arizona Cardiovascular Research Center, Phoenix, Arizona +60 locations
Conditions: Heart Failure, Heart Failure, Diastolic
Register for Updates
Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
NCT05526560
Recruiting
Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +36 locations
Conditions: Mitral Stenosis, Mitral Valve Insufficiency
Register for Updates
PRISAM: Pre-Operative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Melanoma
NCT05546827
Recruiting
The goal of this clinical research study is to learn if pre-operative radiation therapy after starting immune checkpoint inhibition can help patients with sinonasal or anorectal melanoma have better outcomes
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Sinonasal Melanoma, Anorectal Melanoma
Register for Updates
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
NCT05561127
Recruiting
To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
06/19/2025
Locations: Honor Health, Scottsdale, Arizona +32 locations
Conditions: Bowel; Stricture
Register for Updates
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
NCT05561114
Recruiting
To evaluate the safety and efficacy of the ProTractX3™ DCB for the treatment of benign esophageal strictures.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
06/19/2025
Locations: Birmingham Gastroenterology Associates, Birmingham, Alabama +33 locations
Conditions: Esophageal Stricture
Register for Updates
Pembrolizumab for Advanced NSCLC and PS 2-3
NCT05589818
Recruiting
This single center open-label trial will enroll a single cohort of patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due to 1) disease stage IV, or 2) inability to tolerate intensive surgery or chemo-radiation. Patients will be eligible for the trial if ISMMS reviewed samples from tumor biopsy have a PDL-1 TPS ≥ 1% and have ECOG performance status rated 2 or 3. All patients will receive anti PD-1 therapy with pembrolizumab 200mg IV ev... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Mount Sinai Hospital, New York, New York
Conditions: Non-Small Cell Lung Cancer (NSCLC)
Register for Updates
Lifestyle Intervention for Improving Insulin Resistance and Concern for Health
NCT05649176
Recruiting
The primary objective of this study is to test the effect of a diet and exercise program in older adults with insulin resistance and a motivation disorder known as apathy. The main questions the study aims to answer are: 1. Does the diet and exercise program improve insulin resistance and apathy? 2. Does the addition of soybean to the diet enhance the effect? Participants will be given all meals for 12 weeks and will exercise under supervision. They will undergo a test of insulin sensitivity an... Read More
Gender:
ALL
Ages:
Between 50 years and 75 years
Trial Updated:
06/19/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Insulin Sensitivity, Apathy
Register for Updates